PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests an experimental drug called epcoritamab (GEN3013) in people with several types of B-cell lymphoma that have relapsed (come back) or are refractory (did not respond to prior treatment). The main goals are to find the safest and most effective dose, monitor side ef…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Engineered donor cells take on Hard-to-Treat lymphomas
Disease control OngoingThis early-phase study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell lymphoma that have come back or not responded to standard therapy. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The m…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Triple-Target CAR T-Cells take on Hard-to-Treat lymphomas
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Can a simple vaccine boost CAR T-Cell success in lymphoma?
Disease control OngoingThis study looks at whether giving a pneumonia vaccine (PCV13) before and after CAR T-cell therapy can improve the immune system's ability to fight pneumococcus bacteria in people with certain types of lymphoma. About 26 participants with relapsed or hard-to-treat B-cell lymphoma…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 04, 2026 16:29 UTC